160 related articles for article (PubMed ID: 16375696)
21. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
[TBL] [Abstract][Full Text] [Related]
22. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
Zhou J; Wen Q; Li SF; Zhang YF; Gao N; Tian X; Fang Y; Gao J; Cui MZ; He XP; Jia LJ; Jin H; Qiao HL
Oncotarget; 2016 Aug; 7(31):50612-50623. PubMed ID: 27203676
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11.
Nielsen LM; Holm NB; Olsen L; Linnet K
Drug Test Anal; 2016 Aug; 8(8):792-800. PubMed ID: 26360322
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes.
Lang J; Li W; Zhao J; Wang K; Chen D
Xenobiotica; 2017 Oct; 47(10):849-855. PubMed ID: 27819189
[TBL] [Abstract][Full Text] [Related]
25. The Effects of CKD on Cytochrome P450-Mediated Drug Metabolism.
Ladda MA; Goralski KB
Adv Chronic Kidney Dis; 2016 Mar; 23(2):67-75. PubMed ID: 26979145
[TBL] [Abstract][Full Text] [Related]
26. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs.
Islam M; Frye RF; Richards TJ; Sbeitan I; Donnelly SS; Glue P; Agarwala SS; Kirkwood JM
Clin Cancer Res; 2002 Aug; 8(8):2480-7. PubMed ID: 12171873
[TBL] [Abstract][Full Text] [Related]
27. Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices.
Renwick AB; Watts PS; Edwards RJ; Barton PT; Guyonnet I; Price RJ; Tredger JM; Pelkonen O; Boobis AR; Lake BG
Drug Metab Dispos; 2000 Oct; 28(10):1202-9. PubMed ID: 10997941
[TBL] [Abstract][Full Text] [Related]
28. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems.
Krau SD
Nurs Clin North Am; 2013 Dec; 48(4):681-96. PubMed ID: 24295195
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.
Nakamura K; Ariyoshi N; Iwatsubo T; Fukunaga Y; Higuchi S; Itoh K; Shimada N; Nagashima K; Yokoi T; Yamamoto K; Horiuchi R; Kamataki T
Biol Pharm Bull; 2005 May; 28(5):882-5. PubMed ID: 15863898
[TBL] [Abstract][Full Text] [Related]
31. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
32. In vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol.
Usmani KA; Hodgson E; Rose RL
Chem Biol Interact; 2004 Dec; 150(3):221-32. PubMed ID: 15560889
[TBL] [Abstract][Full Text] [Related]
33. Regioselective hydroxylation of steroid hormones by human cytochromes P450.
Niwa T; Murayama N; Imagawa Y; Yamazaki H
Drug Metab Rev; 2015 May; 47(2):89-110. PubMed ID: 25678418
[TBL] [Abstract][Full Text] [Related]
34. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies.
Kranendonk M; Carreira F; Theisen P; Laires A; Fisher CW; Rueff J; Estabrook RW; Vermeulen NP
Mutat Res; 1999 Apr; 441(1):73-83. PubMed ID: 10224324
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.
Amsden JR; Gubbins PO
Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1135-1146. PubMed ID: 29022838
[TBL] [Abstract][Full Text] [Related]
36. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
37. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
38. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.
Lee SJ; Goldstein JA
Pharmacogenomics; 2005 Jun; 6(4):357-71. PubMed ID: 16004554
[TBL] [Abstract][Full Text] [Related]
39. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.
Anderson GD
Clin Pharmacokinet; 2005; 44(10):989-1008. PubMed ID: 16176115
[TBL] [Abstract][Full Text] [Related]
40. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.
Lieu C; Shi J; Donat F; Van Horn R; Brian W; Newton J; Delbressine L; Vos R
Clin Pharmacokinet; 2002; 41 Suppl 2():19-26. PubMed ID: 12383041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
